T he treatment of diabetes should be individualised based on each patient's health and personal situation, argued Dr Kevin Fernando, a GP partner in North Berwick, and diabetes lead GP for the East Lothian and Midlothian Community Health Par tner ships, Scotland, speaking at the conference. "Diabetes doesn't really lend itself to an algorithmic approach to treatment. It really requires an individualised approach," he suggested. "Guidelines are helpful to promote effective interventions and discourage ineffective measures, put evidence into practice and achieve consistency of care but we must take into account individual circumstances," he told delegates.
The NICE guidance on type 2 diabetes in adults, 1 published in 2015, emphasised individualised care. "But it also included a rather clunky algorithm," he suggested. He considered the SIGN guidance 2 to be more pragmatic, recommending that HbA1c targets should be set for individuals in order to balance benefits with harms. The SIGN guidance is currently being updated but will maintain this individualised approach in the revised recommendations due out later this year, he explained.
He also suggested that the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guideline 3 is particularly helpful in supporting individualised treatment of type 2 diabetes. "After metformin it's pretty much free for all in terms of drug choice, really illustrating the individualised approach we should take to diabetes care," he said.
Quoting Sir William Osler, who argued: "The good physician treats the disease, the great physician treats the patient who has the disease," Dr Fernando said he found the ADA/EASD diabetes guideline provides a very holistic approach to diabetes care. It suggests taking account of both patient and disease factors, including risks associated with hypoglycaemia, disease duration, life expectancy, co-morbidities and complications, when making treatment decisions.
" ment and what's their support network?" asked Dr Fernando. He considered that the algorithm helps GPs to use these factors to determine how stringently to approach diabetes care, including managing hyperglycaemia, in a particular patient. "For example, if the patient in front of you has a high risk of hypoglycaemia, take your foot off the pedal and adopt a less stringent HbA1c target. The same applies if the patient has a reduced life expectancy," he added.
"We are far too glucocentric in our management of diabetes. Many patients have more to gain from blood pressure and lipid control rather than a tight glycaemic target," Dr Fernando argued. He noted that Scotland has stopped using the Quality and Outcomes Framework (QOF). Although it improved the quality of chronic disease management, including diabetes, he suggested that one of the disadvantages was it endorsed a 'tick box' approach to medicine, using a 'onesize-fits-all' method. "That's not the case for diabetes. It requires an individualised approach," he maintained.
Questions to ask to achieve a more individualised approach to diabetes treatment
The first question to ask is: "Why are we treating this person with diabetes?" Dr Fernando proposed. "Is it to improve their quality of life, to reduce osmotic symptoms such as polyuria or polydipsia, to prevent microvascular and macrovascular complications, or all these?" He suggested a patient's age was irrelevant, with functional status being more important. "If the patient is 90 years of age and is living an active life with potentially 10 more years of life expectancy, then aim for slightly tighter glycaemic, blood pressure and lipid targets. But if the patient is 50 years old with multiple co-morbidities and is housebound, then take your foot off the pedal in terms of glycaemic control, and even in blood pressure and lipid control, because quality of life is more important for that individual rather than thinking about quantity."
Considering the seminal clinical trials over the last 10 years, the UK Prospective Diabetes Study (UKPDS) provides the basis for much of diabetes care today. It showed that tight glycaemic control (HbA1c <7%) in younger (median age 54 years) patients newly diagnosed with diabetes was associated with lower risk of diabetic complications after 10 years' follow-up. 4 There was also a legacy effect, with benefits of tight glycaemic control continuing after patients returned to standard care. "The key message for those of us in primary care is that in newly diagnosed patients, early, tight control has a long-lasting impact on microvascular and macrovascular complications and mortality. This is why metformin remains standard first-line treatment today."
However, Dr Fernando noted that the Action to Control Cardiovascular Risk in Diabetes study (ACCORD), 5 the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) 6 and Veterans Affairs Diabetes Trial (VADT) 7 studies showed very different effects in a markedly different population of patients. These trials were carried out in older patients (most over 65 years) who had had a longer duration of diabetes of seven to 10 years and had multiple complications and co-morbidities, most with established cardiovascular disease (CVD). Results showed that tight glycaemic control (HbA1c <6.5%) did not improve cardiovascular outcomes in this much higher risk population of patients compared with those in the UKPDS, and the ACCORD study showed a 22% increase in mortality, leading to the trial being stopped early.
So what are the implications of these findings in clinical practice? "In older patients who have had diabetes for some time and who may have a high risk of CVD or who have established CVD, we need to take our foot off the pedal for glycaemic control because of the risk of doing more harm than good," Dr Fernando advised, adding: "These patients have more to gain from tight blood pressure control." He pointed out that hyperglycaemia is a much weaker risk factor for CVD than raised blood pressure or cholesterol (see Table 1 ). "It's important to put into perspective the hierarchy of glucose control compared to cholesterol and blood pressure control when it comes to reducing cardiovascular death," he suggested.
Choosing the right drug for the right patient
There is a wide range of drugs now available to treat type 2 diabetes, each with a different mode of action and side-effect profile. After decades of choice being limited to metformin and sulfonylureas, several new classes of drug have more recently been licensed. "Over the last five to 10 years, we've had an explosion in new classes of diabetes drug. So the challenge is to match the drug to the individual patient," explained Dr Fernando. "Each of these classes of drug has its own mode of action and particular side-effects."
He suggested that prescribers take account of several factors to individualise diabetes treatment (see Table 2 ). • Patient preference. Does the patient want another drug and what are their concerns about hypoglycaemia, weight gain and other side-effects? "Patient preference is paramount," he suggested.
• Functional status. In a patient with good functional status, the benefits of tighter glycaemic control may outweigh the potential risks, supporting use of a more potent drug to achieve a greater reduction in HbA1c. For a patient with poorer functional status, who may be frail and less independent, it may be appropriate to aim for less intensive glycaemic control and consider a less potent hypoglycaemic agent, such as a dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin).
• Disease duration. Early in diabetes, there is a lot to be gained from tight glycaemic control but there may be less benefit with longer-term disease (over seven to 10 years).
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Summing up, Dr Fernando recommended paying careful attention to individual patient preferences and characteristics to optimise the management of diabetes. "Individualise diabetes treatment as much as possible," he concluded. www.prescriber.co.uk
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